한글목차

세계 합성생물학 시장 규모는 2024년 123억 3,000만 달러에서 2029년 315억 2,000만 달러에 이르고, 연평균 20.6%의 높은 성장률을 나타낼 것으로 예상됩니다.

바이오 제품에 대한 과도한 수요가 시장 성장에 탄력을 주고 있습니다. 또한, 국내외 시장의 요구에 부응하기 위한 주요 시장 기업들의 투자 증가와 합성생물학 시장의 R&D 및 공동연구에 대한 자금 지원 증가는 시장 성장을 더욱 촉진하고 있으며, CRISPR을 비롯한 유전자 편집 기술의 개발은 합성생물학 부문에 새로운 길을 열어주었습니다. 이러한 첨단 기술은 정확한 유전자 조작을 가능하게 하고, 치료 응용 및 농업 발전을 가속화하여 합성생물학 시장의 성장을 가속하고 있습니다.

"올리고뉴클레오티드 및 합성 DNA 합성 생물학 부문이 2023년 가장 높은 점유율을 차지할 것으로 예상됩니다."

올리고뉴클레오티드 및 합성 DNA는 시장을 장악하고 예측 기간 동안 높은 CAGR로 성장할 것으로 예상됩니다. 환경, 식품 및 산업 부문에서 올리고뉴클레오티드 및 합성 DNA의 사용 증가와 농업, 에너지 및 산업 생명 공학 등의 분야에서 합성 생물학 기업의 확장은 부문 성장의 주요 촉진요인입니다.

"용도별로는 의료용이 가장 큰 시장 점유율을 차지했습니다."

의료 분야는 만성질환과 유전성 질환 증가로 인해 혁신적인 의료 솔루션에 대한 수요가 증가함에 따라 시장 점유율을 독식했습니다. 또한, 유전자 편집과 합성 미생물의 발전으로 연구자들은 표적 치료, 개인 맞춤형 의료, 인공 백신을 개발할 수 있게 되었습니다.

"북미: 합성생물학 시장에서 가장 큰 점유율"

북미가 2023년 합성생물학 시장을 장악하고 예측 기간 동안에도 우위를 유지할 것으로 예상됩니다. 이 지역의 제약 및 바이오테크놀러지 기업들과 Thermo Fisher Scientific Inc. 및 Agilent Technologies Inc.와 같은 합성생물학 제조업체들의 탄탄한 기반이 시장 성장을 가속하는 주요 요인으로 작용할 것으로 보입니다.

본 보고서는 세계 합성생물학 시장에 대해 조사 분석했으며, 주요 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

• 합성생물학 시장 개요
• 북미의 합성생물학 시장 : 용도별, 국가별(2023년)
• 합성생물학 시장 점유율 : 용도별(2024년·2029년)
• 합성생물학 시장 : 지역별

제5장 시장 개요

• 서론
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 밸류체인 분석
• 생태계 분석
  • 제품/서비스 제공업체
  • 최종사용자
  • 규제 상황
• 기술 분석
  • 주요 기술
  • 보완 기술
  • 인접 기술
• 특허 분석
  • 조사 방법
  • 출원 특허수
  • 혁신과 특허 출원
• 가격 분석
  • 제품 참고 가격 분석 : 주요 기업별
  • 제품 참고 가격 분석 : 지역별
• 주요 컨퍼런스 및 이벤트(2024년-2025년)
• 규제 상황
  • 규제기관, 정부기관, 기타 조직
  • 규제 구조
• 투자와 자금조달 시나리오
• Porter의 Five Forces 분석
• 주요 이해관계자와 구입 기준
• 합성생물학 시장에 대한 AI 영향

제6장 합성생물학 시장 : 툴별

• 서론
• 올리고뉴클레오티드 및 합성 DNA
• 효소
• 클론 기술 키트
• 합성 세포
• 섀시 유기체
• 이종 핵산

제7장 합성생물학 시장 : 기술별

• 서론
• 유전자 합성
• 유전체 엔지니어링
• 시퀀싱
• 바이오인포매틱스
• 클로닝
• 부위 특이적 변이 도입
• 측정 및 모델링
• 마이크로플루이딕스
• 나노테크놀러지

제8장 합성생물학 시장 : 용도별

• 서론
• 의료 용도
  • 의약품
  • Drug Discovery 및 치료
  • 인공 조직 및 조직 재생
• 산업 용도
  • 바이오연료 및 재생에너지
  • 산업용 효소
  • 바이오소재 및 그린 케미컬
• 식품/동물 의료/농업 용도
  • 향료
  • 기타 식품, 동물 의료, 농업 용도
• 환경 용도
  • 바이오레메디에이션
  • 바이오 센싱

제9장 합성생물학 시장 : 지역별

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 스위스
  • 덴마크
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 라틴아메리카의 거시경제 전망
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
• 중동
  • 중동의 거시경제 전망
  • GCC 국가
  • 기타 중동
• 아프리카

제10장 경쟁 구도

• 개요
• 주요 기업의 전략/유력 기업
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 기업(2023년)
• 기업 평가 매트릭스 : 스타트업/중소기업(2023년)
• 기업 평가와 재무 지표(2023년)
• 브랜드/제품 비교
• 경쟁 시나리오

제11장 기업 개요

• 주요 기업
  • THERMO FISHER SCIENTIFIC INC.
  • MERCK KGAA
  • NOVOZYMES A/S
  • EUROFINS SCIENTIFIC
  • AGILENT TECHNOLOGIES INC.
  • AMYRIS, INC.
  • CODEXIS, INC.
  • TWIST BIOSCIENCE
  • GENSCRIPT
  • PRECIGEN
  • GINKGO BIOWORKS
  • VIRIDOS
  • SYNTHEGO
  • CREATIVE ENZYMES
  • CYRUS BIOTECHNOLOGY
• 기타 기업
  • ATUM
  • TESELAGEN
  • ARZEDA
  • INTEGRATED DNA TECHNOLOGIES, INC.
  • NEW ENGLAND BIOLABS
  • ELEVATEBIO
  • ZENFOLD(IOSYNTH)
  • SYNBIO TECHNOLOGIES
  • INSCRIPTA, INC.
  • CRISPR THERAPEUTICS

제12장 부록

영문목차

The global synthetic biology market is projected to surpass USD 31.52 billion in 2029 from USD 12.33 billion in 2024, with a significant CAGR of 20.6%. The excessive demand for bio-based products is providing momentum to the market growth. Furthermore, rising investment by key market players and increasing funding in R&D & collaborations in the synthetic biology market to meet the needs of both local and international markets is further driving the market growth. The development of CRISPR and other gene-editing technologies opened new avenues for the synthetic biology sector. These advanced technologies enable precise gene modifications, accelerating advancements in therapeutic applications and agriculture fueling the growth of the synthetic biology market.

"The oligonucleotide & synthetic DNA synthetic biology segment accounted for the highest share in 2023."

On the basis of tools, the synthetic biology market is further segmented into xeno nucleic acids, enzymes, chassis organisms, cloning technology kits, oligonucleotides and synthetic DNA, and synthetic cells. The oligonucleotides and synthetic DNA dominated the market and anticipated to grow at a significant CAGR during the forecast period. Rise in the use of oligonucleotides and synthetic DNA in environmental, food, and industrial sectors, expansion of synthetic biology companies in in areas such as agriculture, energy, and industrial biotechnology are some of the major factors driving the segmental growth.

"By applications, medical applications segment accounted for the largest share in the synthetic biology market."

The applications segment in the synthetic biology market is segmented into medical applications, industrial applications, food, animal health & agricultural applications and environmental applications. The medical applications segment dominated the market share owing to the increasing prevalence of chronic diseases and genetic disorders which is driving demand for innovative medical solutions. Furthermore, with advancements in gene editing and synthetic microbes, researchers can develop targeted therapies, personalized medicine, and even engineered vaccines.

"North America: the largest share of the synthetic biology market"

By region, the market is segment into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the synthetic biology market in 2023 and is estimated to continue dominance during the forecast period. Presence of dominant market players in pharmaceutical and biotechnological companies in the region, strong base of synthetic biology manufacturers such as Thermo Fisher Scientific Inc. and Agilent Technologies Inc. are some of the prominent factors acerating market growth.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the synthetic biology market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Novozymes A/S (Denmark), Agilent Technologies Inc. (US), Eurofins Scientific (Luxembourg), Amyris, Inc. (US), Twist Bioscience (US), Codexis, Inc. (US), Genscript (US), Ginkgo Bioworks (US), Precigen (US), Creative Enzymes (US), Synthego (US), Viridos (US), and Cyrus Biotechnology (US) are some of the major players operating in the synthetic biology market.

Research Coverage:

This research report categorizes the synthetic biologys market tools (oligonucleotides & synthetic DNA, enzymes, cloning technology kits, chassis organisms, xeno nucleic acids and synthetic cells), technologies (measurement and modeling, genome engineering, gene synthesis, cloning, site-directed mutagenesis, microfluidics, sequencing, nanotechnology and bioinformatics), and applications (medical applications, industrial applications, food, animal health & agricultural applications and environmental applications) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the synthetic biologys market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the synthetic biology market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the synthetic biology and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (diverse applications of synthetic biology, increasing demand for bio-based products, advancements in synthetic biology, rising funding in R&D and collaborations), restraints (production scalability, ethical and regulatory challenges), opportunities (rising opportunities for agricultural synthetic biology, growing use of artificial intelligence and machine learning) and Challenges (Cost constraints) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on upcoming technologies in synthetic biology manufacturing, research and development activities, and new product launches in the synthetic biology market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the synthetic biology market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Novozymes A/S (Denmark), Eurofins Scientific (Luxembourg), Agilent Technologies Inc. (US), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET SIZE ESTIMATION
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 SYNTHETIC BIOLOGY MARKET OVERVIEW
• 4.2 NORTH AMERICA: SYNTHETIC BIOLOGY MARKET, BY APPLICATION AND COUNTRY (2023)
• 4.3 SYNTHETIC BIOLOGY MARKET SHARE, BY APPLICATION, 2024 VS. 2029
• 4.4 SYNTHETIC BIOLOGY MARKET, BY REGION

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Diverse applications of synthetic biology
    • 5.2.1.2 Surging demand for bio-based products
    • 5.2.1.3 Advancements in synthetic biology
    • 5.2.1.4 Increasing funding in R&D and collaborations
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Production scalability
    • 5.2.2.2 Ethical and regulatory challenges
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising opportunities for agricultural synthetic biology
    • 5.2.3.2 Growing integration of artificial intelligence and machine learning
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Cost constraints
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 PRODUCT/SERVICE PROVIDERS
  • 5.5.2 END USERS
  • 5.5.3 REGULATORY LANDSCAPE
• 5.6 TECHNOLOGY ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 DNA synthesis and sequencing
    • 5.6.1.2 Gene editing tools
    • 5.6.1.3 Bioinformatics and computational tools
    • 5.6.1.4 Nanotechnology
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Cellular and tissue engineering
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Metabolic engineering
• 5.7 PATENT ANALYSIS
  • 5.7.1 METHODOLOGY
  • 5.7.2 NUMBER OF PATENTS FILED
  • 5.7.3 INNOVATION AND PATENT APPLICATIONS
• 5.8 PRICING ANALYSIS
  • 5.8.1 INDICATIVE PRODUCT PRICING ANALYSIS, BY KEY PLAYER
  • 5.8.2 INDICATIVE PRODUCT PRICING ANALYSIS, BY REGION
• 5.9 KEY CONFERENCES & EVENTS, 2024-2025
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 REGULATORY FRAMEWORK
• 5.11 INVESTMENT & FUNDING SCENARIO
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12.2 BARGAINING POWER OF SUPPLIERS
  • 5.12.3 BARGAINING POWER OF BUYERS
  • 5.12.4 THREAT OF SUBSTITUTES
  • 5.12.5 THREAT OF NEW ENTRANTS
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 KEY BUYING CRITERIA
• 5.14 IMPACT OF AI ON SYNTHETIC BIOLOGY MARKET

6 SYNTHETIC BIOLOGY MARKET, BY TOOL

• 6.1 INTRODUCTION
• 6.2 OLIGONUCLEOTIDES & SYNTHETIC DNA
  • 6.2.1 SURGING DEMAND FOR SYNTHETIC GENES TO SUPPORT MARKET GROWTH
• 6.3 ENZYMES
  • 6.3.1 WIDE POTENTIAL OF ENZYME ENGINEERING IN OMICS STUDIES TO PROPEL MARKET
• 6.4 CLONING TECHNOLOGY KITS
  • 6.4.1 ALTERATION AND OPTIMIZATION OF GENETIC CIRCUIT DESIGNS BY MOLECULAR BIOLOGY TECHNIQUES TO DRIVE MARKET
• 6.5 SYNTHETIC CELLS
  • 6.5.1 GROWING POPULARITY OF SYNTHETIC CELLS AS SUBSTITUTES FOR NATURAL CELLS TO BOOST MARKET GROWTH
• 6.6 CHASSIS ORGANISMS
  • 6.6.1 INCREASING DEMAND FOR FOSSIL FUELS TO PROPEL MARKET
• 6.7 XENO NUCLEIC ACIDS
  • 6.7.1 SPIKE IN DEMAND FOR BREAKTHROUGH MEDICINES TO AID MARKET GROWTH

7 SYNTHETIC BIOLOGY MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 GENE SYNTHESIS
  • 7.2.1 RISING DEMAND FOR SYNTHETIC GENES AND INCREASING COMPETITIVENESS AMONG MARKET PLAYERS TO SPUR MARKET GROWTH
• 7.3 GENOME ENGINEERING
  • 7.3.1 SURGING NEED FOR RAPID, CHEAP, AND MULTIPLEX MODIFICATION OF GENOMES TO DRIVE MARKET
• 7.4 SEQUENCING
  • 7.4.1 RISING ADOPTION OF SEQUENCING TECHNOLOGY TO BOOST MARKET GROWTH
• 7.5 BIOINFORMATICS
  • 7.5.1 INCREASING ADVANCEMENTS AND RISING USE OF BIOINFORMATICS TO PROPEL MARKET GROWTH
• 7.6 CLONING
  • 7.6.1 PRECISE GENETIC REPLICATION TO ACCELERATE RESEARCH AND SCALING APPLICATIONS ACROSS VARIOUS INDUSTRIES
• 7.7 SITE-DIRECTED MUTAGENESIS
  • 7.7.1 WIDE APPLICATIONS IN GENETIC ENGINEERING, DNA ASSEMBLY, AND CLONING TECHNOLOGIES TO DRIVE MARKET
• 7.8 MEASUREMENT & MODELING
  • 7.8.1 INCREASING DEMAND FOR CELL-FREE SYNTHETIC BIOLOGY TO FOSTER MARKET GROWTH
• 7.9 MICROFLUIDICS
  • 7.9.1 RISING FOCUS ON INCREASING SCALABILITY OF SYNTHETIC BIOLOGY TOOLS TO PROPEL MARKET GROWTH
• 7.10 NANOTECHNOLOGY
  • 7.10.1 CONVERGENCE BETWEEN SYNTHETIC BIOLOGY AND NANOTECHNOLOGY TO AID MARKET GROWTH

8 SYNTHETIC BIOLOGY MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 MEDICAL APPLICATIONS
  • 8.2.1 PHARMACEUTICALS
    • 8.2.1.1 Potential of synthetic biology techniques in development of active pharmaceutical ingredients to drive market
  • 8.2.2 DRUG DISCOVERY & THERAPEUTICS
    • 8.2.2.1 Cancer detection & diagnostics
      • 8.2.2.1.1 Increasing investments in cancer research to support market growth
    • 8.2.2.2 Other drug discovery & therapeutic applications
  • 8.2.3 ARTIFICIAL TISSUE & TISSUE REGENERATION
    • 8.2.3.1 Biosynthesis
      • 8.2.3.1.1 Expansive design space enabled by synthetic biology to foster market growth
    • 8.2.3.2 Stem cell regulation
      • 8.2.3.2.1 Stem cell research to accelerate market growth
    • 8.2.3.3 Other artificial tissue & tissue regeneration applications
• 8.3 INDUSTRIAL APPLICATIONS
  • 8.3.1 BIOFUELS & RENEWABLE ENERGY
    • 8.3.1.1 Advantages of using genetically engineered organisms for synthetic production of biofuels to propel market growth
  • 8.3.2 INDUSTRIAL ENZYMES
    • 8.3.2.1 Textile industry
      • 8.3.2.1.1 Surge in demand for increasing reaction rates and reducing costs to foster market growth
    • 8.3.2.2 Paper industry
      • 8.3.2.2.1 Increasing use of enzymes in pulp and paper industry to favor market growth
    • 8.3.2.3 Consumer care industry
      • 8.3.2.3.1 Skincare & cosmetics
        • 8.3.2.3.1.1 Benefits offered by synthetic biology technologies in manufacturing of skincare and cosmetic products to propel market growth
      • 8.3.2.3.2 Other consumer care products
    • 8.3.2.4 Other industries
  • 8.3.3 BIOMATERIALS & GREEN CHEMICALS
    • 8.3.3.1 Production of green chemicals through microbial fermentation to drive market
• 8.4 FOOD, ANIMAL HEALTH, AND AGRICULTURAL APPLICATIONS
  • 8.4.1 FLAVORS & FRAGRANCES
    • 8.4.1.1 Rising demand for natural, sustainable products to bolster market growth
  • 8.4.2 OTHER FOOD, ANIMAL HEALTH, AND AGRICULTURAL APPLICATIONS
• 8.5 ENVIRONMENTAL APPLICATIONS
  • 8.5.1 BIOREMEDIATION
    • 8.5.1.1 Increasing need for cost-effective, on-site environmental monitoring methods to boost market
  • 8.5.2 BIOSENSING
    • 8.5.2.1 Growing interest in development of whole-cell biosensors to drive market

9 SYNTHETIC BIOLOGY MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 9.2.2 US
    • 9.2.2.1 Rising investment in synthetic biology companies and surging demand for bio-based products to drive market
  • 9.2.3 CANADA
    • 9.2.3.1 Strong research infrastructure and availability of funding to support market growth
• 9.3 EUROPE
  • 9.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 9.3.2 GERMANY
    • 9.3.2.1 Government initiatives and increasing funding to propel market growth
  • 9.3.3 UK
    • 9.3.3.1 Increasing R&D expenditure to favor market growth
  • 9.3.4 FRANCE
    • 9.3.4.1 Investments aimed at increasing research in various biomedical fields to augment market growth
  • 9.3.5 SWITZERLAND
    • 9.3.5.1 Established biotech ecosystem, strong academic institutions, and favorable government policies to favor market growth
  • 9.3.6 DENMARK
    • 9.3.6.1 Presence of third-largest commercial drug development pipeline in Europe to favor market growth
  • 9.3.7 ITALY
    • 9.3.7.1 Increasing life sciences R&D funded by both public and private organizations to foster market
  • 9.3.8 SPAIN
    • 9.3.8.1 Well-established network of research centers, universities, and hospitals to support market growth
  • 9.3.9 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 9.4.2 CHINA
    • 9.4.2.1 Rising growth opportunities for pharmaceutical and biopharmaceutical companies to drive market
  • 9.4.3 JAPAN
    • 9.4.3.1 Growing awareness of synthetic biology's importance and potential applications to accelerate market growth
  • 9.4.4 INDIA
    • 9.4.4.1 Increasing R&D activities and government funding initiatives to bolster market growth
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Increasing funding for synthetic biology research to accelerate market growth
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Increasing focus on developing biotechnology and pharmaceutical sectors to boost market
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 9.5.2 BRAZIL
    • 9.5.2.1 Growing life sciences and pharmaceutical industry to fuel demand for synthetic biological products
  • 9.5.3 MEXICO
    • 9.5.3.1 Increasing support for biotechnology infrastructure development to augment market growth
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST
  • 9.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 KSA
    • 9.6.2.2 UAE
    • 9.6.2.3 Rest of GCC countries
  • 9.6.3 REST OF MIDDLE EAST
• 9.7 AFRICA
  • 9.7.1 AFRICA: MACROECONOMIC OUTLOOK

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN SYNTHETIC BIOLOGY MARKET
• 10.3 REVENUE ANALYSIS
• 10.4 MARKET SHARE ANALYSIS
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Tool footprint
    • 10.5.5.4 Technology footprint
    • 10.5.5.5 Application footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 10.7 COMPANY VALUATION & FINANCIAL METRICS, 2023
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 THERMO FISHER SCIENTIFIC INC.
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products/Services offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product launches
      • 11.1.1.3.2 Deals
      • 11.1.1.3.3 Expansions
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 MERCK KGAA
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products/Services offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 NOVOZYMES A/S
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products/Services offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 EUROFINS SCIENTIFIC
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products/Services offered
  • 11.1.5 AGILENT TECHNOLOGIES INC.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products/Services offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Products launches
      • 11.1.5.3.2 Deals
      • 11.1.5.3.3 Expansions
  • 11.1.6 AMYRIS, INC.
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products/Services offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Deals
  • 11.1.7 CODEXIS, INC.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products/Services offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches
      • 11.1.7.3.2 Deals
      • 11.1.7.3.3 Expansions
  • 11.1.8 TWIST BIOSCIENCE
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products/Services offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product launches
      • 11.1.8.3.2 Deals
      • 11.1.8.3.3 Expansions
  • 11.1.9 GENSCRIPT
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products/Services offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Product launches
      • 11.1.9.3.2 Deals
      • 11.1.9.3.3 Other developments
  • 11.1.10 PRECIGEN
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products/Services offered
  • 11.1.11 GINKGO BIOWORKS
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products/Services offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Product launches
      • 11.1.11.3.2 Deals
  • 11.1.12 VIRIDOS
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products/Services offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Product launches
      • 11.1.12.3.2 Deals
      • 11.1.12.3.3 Other developments
  • 11.1.13 SYNTHEGO
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products/Services offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product launches
      • 11.1.13.3.2 Deals
      • 11.1.13.3.3 Expansions
  • 11.1.14 CREATIVE ENZYMES
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products/Services offered
  • 11.1.15 CYRUS BIOTECHNOLOGY
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products/Services offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Deals
• 11.2 OTHER PLAYERS
  • 11.2.1 ATUM
  • 11.2.2 TESELAGEN
  • 11.2.3 ARZEDA
  • 11.2.4 INTEGRATED DNA TECHNOLOGIES, INC.
  • 11.2.5 NEW ENGLAND BIOLABS
  • 11.2.6 ELEVATEBIO
  • 11.2.7 ZENFOLD (IOSYNTH)
  • 11.2.8 SYNBIO TECHNOLOGIES
  • 11.2.9 INSCRIPTA, INC.
  • 11.2.10 CRISPR THERAPEUTICS

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS